Meetings

LSU’s Pennington Biomedical Research Center will host its 2026 Childhood Obesity Conference, “Be the Reason Kids Greaux Healthy,” on Sept. 24 at the C.B. Pennington, Jr. Conference Center. The conference, presented by the Greaux Healthy initiative, will bring together health care professionals, researchers, educators and community leaders to explore strategies for preventing and treating childhood obesity.

ARDD 2026 has announced that senior officials from the U.S. Food and Drug Administration (FDA) will join the Advanced Research Projects Agency for Health (ARPA-H) for a dedicated government and regulatory panel at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University.

The session, “Matching Clinical Trials of Therapeutics & Regulatory Mandates,” will bring together Jeffrey Siegel, Director, Office of Drug Evaluation Sciences, Office of New Drugs, CDER, FDA; Justin Penzenstadler, Associate Director, OCHEN/OND/CDER/FDA; and Lowell M. Zeta, Acting Chief of Staff, Office of the Commissioner, FDA. Andrew Brack, Program Manager, Proactive Health, ARPA-H, will moderate the discussion.

As more discoveries in aging biology advance toward clinical translation, the session will provide an important forum for dialogue between government and regulatory leaders and the researchers, clinicians, and biotechnology innovators developing potential therapies to extend healthy lifespan and improve patient outcomes.

August 24–25, 2026 | Hong Kong, China

Alex Aliper, PhD, Co-founder and President of Insilico Medicine, has been invited to attend the Global Unicorn Summit in Hong Kong on August 24. He will participate in a panel discussion titled "What Will Power the Next Wave of Global Growth?" from 15:00 to 15:50.

August 26–28, 2026 | Hong Kong, China

Alex Aliper, PhD, Co-founder and President of Insilico Medicine, has been invited to attend the MedTech World Asia summit in Hong Kong on August 27. He will deliver remarks and join a panel discussion titled "AI & Precision Medicine: Turning Data into Targeted Care" from 12:35 to 13:10. Subsequently, Dr.Aliper will attend a luncheon titled "Cross-Border Exit Architecture for Asian MedTech Companies" on August 28, from 12:45 pm to 13:45 pm.

The University of Hong Kong (HKU) has successfully secured the hosting rights for the 2028 Magnetospheres of Outer Planets (MOP) Conference. As the premier global symposium in space physics, MOP has been held biennially since the 1970s and will make its historic debut in Hong Kong in 2028, more than half a century after its inception. Jointly hosted by the Hong Kong Institute for Astronomy and Astrophysics (HKIAA) and the Laboratory for Space Research (LSR) at HKU, this landmark event marks a major milestone in establishing Hong Kong’s leadership in space and planetary sciences across the Asia-Pacific region and globally.

A large international study of more than 14,000 patients with non-small cell lung cancer found that younger adults were significantly more likely than older patients to have genetic alterations that can be targeted with existing therapies. The findings suggest age may be an overlooked factor in lung cancer biology and treatment decisions.

Insilico Medicine has announced the program for ARDD 2026, the 13th Aging Research & Drug Discovery Meeting, taking place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston.

The three-day program will convene global leaders from pharmaceutical and biotechnology companies, academia, clinical medicine, investment, artificial intelligence, scientific publishing and policy. Sessions will span aging biology, therapeutic discovery, clinical development, regulatory strategy, partnering and investment, reflecting the growing maturity of longevity biotechnology.

Insilico Medicine has announced the program for ARDD 2026, the 13th Aging Research & Drug Discovery Meeting, taking place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston.

The three-day program will convene global leaders from pharmaceutical and biotechnology companies, academia, clinical medicine, investment, artificial intelligence, scientific publishing and policy. Sessions will span aging biology, therapeutic discovery, clinical development, regulatory strategy, partnering and investment, reflecting the growing maturity of longevity biotechnology.

ARDD 2026 has announced that George Church, Professor at Harvard Medical School, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

Optica will host the Global Photonics Economic Forum (GPEF) 2026 on 24–25 September in Málaga, Spain, bringing together over 400 executive leaders, investors, and policymakers. As the premier event dedicated to the business and economic future of photonics, GPEF 2026 will explore key drivers like AI infrastructure, quantum tech, supply chain resilience, and market investment. Featuring C-suite speakers from Arista Networks, Lumentum, ams OSRAM, and Coherent, the forum includes high-level discussions, networking, and the 2026 Optica i4 Prize celebration. Early Bird registration rates end 04 September 2026.